The gut and skin microbiota are microbial barriers, resisting harmful foreign microorganisms and maintaining internal homeostasis. Dysbiosis of the gut and skin microbiota is involved in aging progression. However, interventions targeting facial skin wellness taking into account the gut–skin axis are scarce. In this study, the impact of an eight-week intervention with oral (O), topical (T), and both oral and topical (OT) xylo-oligosaccharides (XOS) by regulating gut and skin microbiota on facial cutaneous aging was investigated in a double-blind placebo-controlled trial in females. An increase in the proportion of participants with skin rejuvenation was observed, along with a significant reduction in facial pores after OT intervention. The reduction of cutaneous Cutibacterium by OT intervention was greater than that in the O and T groups. These interventions can change the skin microbial structure. Intestinal Bifidobacterium was enriched only by dual treatment with oral and topical XOS. Function prediction analysis revealed a decrease in K02770 encoding fructose-1-phosphate kinase involved in de novo lipid synthesis from fructose with dual intervention, suggesting that inhibition of lipophilic Cutibacterium may contribute to reducing facial pores. Overall, the dual XOS intervention approach is most effective for improving both gut and skin microbiota, as well as facial skin aging.

中文翻译：

---

对肠道和皮肤微生物群的双重干预可减轻面部皮肤衰老

肠道和皮肤微生物群是微生物屏障，抵抗有害的外来微生物并维持内部稳态。肠道和皮肤微生物群的失调与衰老进程有关。然而，考虑到肠道-皮肤轴的针对面部皮肤健康的干预措施却很少。在这项研究中，通过调节肠道和皮肤微生物群，研究了口服 (O)、局部 (T) 以及口服和局部 (OT) 低聚木糖 (XOS) 为期八周的干预对面部皮肤衰老的影响。一项针对女性的双盲安慰剂对照试验。观察到，OT 干预后，皮肤年轻化的参与者比例有所增加，面部毛孔也显着减少。 OT干预对皮肤皮肤杆菌的减少幅度大于O组和T组。这些干预措施可以改变皮肤微生物结构。仅通过口服和局部低聚木糖双重治疗才能富集肠道双歧杆菌。功能预测分析显示，通过双重干预，编码果糖-1-磷酸激酶的 K02770 减少，该激酶参与从果糖从头合成脂质，这表明抑制亲脂性皮肤杆菌可能有助于缩小面部毛孔。总体而言，双低聚木糖干预方法对于改善肠道和皮肤微生物群以及面部皮肤老化最有效。